Par Pharmaceutical has entered into an exclusive acquisition and pharma licensing agreement with Handa Pharmaceuticals to acquire Handa's Abbreviated New Drug Application for quetiapine fumarate extended-release tablets, the generic version of AstraZeneca's Seroquel XR.
Under the terms of this pharma licensing and marketing agreement, Par has made a payment for the ANDA and for exclusive rights to market, sell and distribute quetiapine fumarate extended-release tablets in the U.S. under the ANDA, subject to its final approval by the U.S. Food and Drug Administration.
Par will receive a share of profits from the sales of the product.
Under the terms of a prior settlement agreement with AstraZeneca, which has been assigned to Par, Par has a license to enter the U.S. market with quetiapine fumarate extended-release tablets on November 1, 2016 or earlier under certain circumstances
For further deal information visit Current Agreements (subscription required)
Read: more on partnering deals in pharma, biotech, life science partnering deal news, insights and glossary
Report: Generic Pharma Partnering Yearbook 2013
View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value
View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making
View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity